Relief Therapeutics Announces Executive Changes

GENEVA (June 3, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY), a biopharmaceutical company dedicated to innovative treatment options for select specialty, unmet and rare diseases, has announced several executive changes. Interim Chief Executive Officer Michelle Lock has completed her transitional mandate, and her contract was not renewed as of May 31, 2024.

Ms. Lock will also not stand for re-election to the Company’s Board of Directors at the forthcoming annual general meeting. Additionally, the Company has seen transitions with Andrew Einhorn and Melinda Keegan stepping down as Chief Financial Officer and Chief Human Resources Officer, respectively. Jeremy Meinen will remain with the Company in a senior role.

The Board of Directors is committed to maximizing the value of the company's therapeutic product portfolio. A comprehensive review will be undertaken to ensure the senior management team is properly sized and capable of delivering meaningful, positive results. The Board will temporarily oversee company operations, ensuring daily activities continue without disruption.